secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001847903-25-000090
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears IND for Centessa's ORX142, Phase 1 study in sleep-deprived volunteers planned
--------------------------------------------------------------------------------

- FDA cleared IND for ORX142, a novel OX2R agonist for neurological/neurodegenerative disorders.
- Phase 1 study will evaluate safety, PK, and PD (MWT, KSS) in acutely sleep-deprived healthy adults.
- Clinical data from Phase 1 expected this year; study initiation imminent.
- ORX142 is second orexin franchise candidate; ORX750 in Phase 2a for narcolepsy/IH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790325000090/0001847903-25-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790325000090/cnta-20250616.htm
  HTML page:      https://secwatch.observer/filing/0001847903-25-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer